IHS Technology

Wound healing is a complex process with a linear development that involves many actors in a multistep timeline commonly divided into four stages: Hemostasis, inflammation, proliferation, and remodeling. Chronic non-healing wounds fail to progress beyond the inflammatory phase, thus precluding the next steps and, ultimately, wound repair. Many intrinsic or extrinsic factors may contribute to such an occurrence, including patient health conditions, age-related diseases, metabolic deficiencies, advanced age, mechanical pressure, and infections. The paracrine activity of Adipose tissue-derived stem cell’s (ASC) has been found to have a therapeutic impact on chronic non-healing wounds.  

Recombinant growth factors are proteins (polypeptides) that occur naturally in the body and are integral in the wound healing process. Research has determined that they stimulate cell growth and migration. Clinical efficacy has been demonstrated when they are used as an integral component of a comprehensive wound management program. Indicated for lower-extremity diabetic neuropathic ulcers. They are manufactured through recombinant DNA technology. 

IHS utilizes monitoring technology combined with proprietary regenerative technology (ASC) developed over the past several years, to produce cutting edge next generation wound dressings.  IHS wound dressings will address the urgent need for timely healing of chronic wounds that have in the past either proven to be non-healing and/or require extended periods of time to heal.  
Share by: